Purpose: Urinary tract infections (UTIs) are among the most common community-acquired infections in patients with cancer. Though the prevalence of multi-drug resistant organisms (MDROs) has increased, there are limited studies on MDROs among ambulatory cancer patients with UTIs. Therefore, we aimed to evaluate the prevalence and predictors of MDROs in this patient population.
Patients And Methods: A retrospective study of adult cancer patients treated for bacterial UTIs in the ambulatory setting at King Hussein Cancer Center. The medical laboratory's system was used to identify positive urine cultures taken in the ambulatory setting, between Aug 2020 and March 2021. UTIs were defined as a positive urine culture along with the initiation of antibiotics empirically or as definitive therapy. Patient characteristics, as well as the type and sensitivity of the bacterial organisms, were recorded. MDROs were defined as intrinsic or acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Logistic regression was used to identify predictors that were independently associated with MDROs.
Results: A total of 376 patients had UTIs that met the inclusion criteria; mean age 60.5±15.1 (SD) years and 330 (87.8%) had solid tumors. Gram-negative bacteria was recorded in the majority of UTIs (n = 368, 97.9%), the most common being (n = 220, 59.8%) and (n = 68, 18.5%). MDROs were recorded in 226 (60.1%) of urine cultures, with the majority being extended-spectrum-beta-lactamase producing organisms (n = 142, 62.8%). The only significant predictor was having had a UTI with MDRO within the past 6 months (OR 5.6, 95% CI 2.1-15.2).
Conclusion: More than half of the positive urine cultures of cancer patients treated for UTIs in the ambulatory setting were MDROs. A subsequent UTI due to MDROs is more likely to occur in patients who had a UTI with an MDRO within the past 6 months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904220 | PMC |
| http://dx.doi.org/10.2147/IDR.S388680 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Mosaic graft" technique and surgical dermal glue in Mohs micrographic surgery and general dermatologic surgery.
Dermatol Reports
February 2025
Centro Dermatologico Vdermastudio, Viareggio.
After Mohs micrographic surgery, derm surgeons utilize local flaps, full or partial thickness grafts, with good or acceptable cosmetic results. When we are dealing with older and problematic patients, blood thinner users, and non-collaborative people with large facial neoplasms, using flaps may be very difficult, and grafts become the best choice. Our aim was to assess a technique to graft very easily, quickly, and safely, full-thickness skin grafts in facial wounds, and have good cosmetic results in those older and problematic people.
View Article and Find Full Text PDFSurvey of the impact of BOLT-trial data on oncologists' and dermatologists' decision-making in treating patients with locally advanced basal cell carcinoma.
Dermatol Reports
February 2025
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples.
Basal cell carcinoma (BCC) is the most common malignant tumor in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic target. In Italy, clinicians can prescribe Hedgehog inhibitors (HhIs) vismodegib and sonidegib.
View Article and Find Full Text PDFIL-15 complex enhances agonistic anti-CD40 + anti-PDL1 by correcting the T-bet to Tox ratio in CD8+ T cells infiltrating pancreatic ductal adenocarcinoma.
Cancer Immunol Res
March 2025
University of Minnesota, Minneapolis, MN, United States.
Agonistic anti-CD40 with anti-PD-1 can elicit objective responses in a small number of patients with pancreatic ductal adenocarcinoma (PDA). Better understanding of their individual effects on the PDA tumor microenvironment will help inform new strategies to further improve outcomes. Herein, we map tumor-specific CD8+ T-cell differentiation following agonistic anti-CD40 and/or anti-PDL1 in PDA.
View Article and Find Full Text PDFEvaluation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care and the Functional Assessment of Chronic Illness Therapy-Palliative in assessing the quality of life in patients with advanced cancer.
Curr Opin Support Palliat Care
March 2025
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Purpose Of Review: Two widely validated health-related quality of life (HR-QoL) tools, specifically designed for patients with advanced cancer, are the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL) and the Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal-14). This systematic review aims to evaluate the use of EORTC QLQ-C15-PAL and FACIT-Pal-14 in prospective studies in patients with advanced cancer, focusing on study types, clinical settings, additional HR-QoL tools used, and completion rates.
Recent Findings: Sixty studies were included in the analysis.
Importance: Exercise intervention studies have shown benefits for patients with lung cancer undergoing surgery, yet most interventions to date have been resource intensive and have followed a one-size-fits-all approach.
Objective: To determine whether a personalized, clinic-aligned perioperative exercise program with remote monitoring and instructions can improve physical function and fatigue among patients undergoing surgery for lung cancer.
Design, Setting, And Participants: The Precision-Exercise-Prescription (PEP) randomized clinical trial is a single-center phase 3 trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!